Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey
- 1 July 1999
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 53 (2), 424
- https://doi.org/10.1212/wnl.53.2.424
Abstract
Article abstract We assessed initial clinical experience with IV tissue plasminogen activator (t-PA) treatment of acute ischemic stroke in a standardized retrospective survey of hospitals with experienced acute stroke treatment systems. The incidence of symptomatic intracerebral hemorrhage (ICH) was 6% (11 of 189 patients; 95% CI 3 to 11%), similar to that in the National Institute of Neurological Disorders and Stroke (NINDS) t-PA Stroke Study. Deviations from the NINDS protocol guidelines were identified in 30% of patients (56 of 189). The incidence of symptomatic ICH was 11% among patients with protocol deviations as compared with 4% in patients who were treated according to the NINDS protocol guidelines, suggesting that strict adherence to protocol guidelines is prudent.Keywords
This publication has 7 references indexed in Scilit:
- Early Intravenous Thrombolysis for Acute Ischemic Stroke in a Community-Based ApproachStroke, 1998
- Cost-effectiveness of tissue plasminogen activator for acute ischemic strokeNeurology, 1998
- Intravenous Tissue Plasminogen Activator for Acute Ischemic StrokeStroke, 1998
- Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic StrokeStroke, 1997
- Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA stroke trialStroke, 1997
- Practice Advisory [RETIRED]Neurology, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995